Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00084071 · ClinicalTrials.gov registry record · Phase 3
Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,136
- Enrollment target
NCT00084071 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 2,136 participants.
The verdict
NCT00084071, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,136 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether tifacogin is effective and safe in the treatment of patients with severe community-acquired pneumonia.
Interventions
- DRUG Tifacogin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,136 participants |
| Start Date | 2004-05 |
| Est. Completion | 2008-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00084071
The ClinicalTrials.gov registry entry for NCT00084071 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tifacogin is the first listed.
NCT00084071 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00084071 about?
NCT00084071 is a clinical study titled "Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia". The purpose of this study is to determine whether tifacogin is effective and safe in the treatment of patients with severe community-acquired pneumonia.
What is the current status of trial NCT00084071?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,136 participants. The study started on 2004-05. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00084071?
The interventions under investigation include: Tifacogin (DRUG).
Who is sponsoring clinical trial NCT00084071?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.